Chronic myeloid leukemia: incorporation of recent advances into current treatment algorithms
{{output}}
Several approved and investigational BCR::ABL1 tyrosine kinase inhibitors (TKIs) and STAMP inhibitors are used for the treatment of chronic myeloid leukemia in chronic phase (CML-CP). In the frontline setting, multiple factors affect selection of therapy inclu... ...
